These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

355 related items for PubMed ID: 9030225

  • 1. [Anti tumor activity of farnesyl transferase inhibitor].
    Yoshimatsu K, Nagasu T.
    Gan To Kagaku Ryoho; 1997 Jan; 24(2):145-55. PubMed ID: 9030225
    [Abstract] [Full Text] [Related]

  • 2. [Inhibitors of isoprenylation of ras p21].
    Yoshimatsu K.
    Gan To Kagaku Ryoho; 1997 Sep; 24(11):1495-502. PubMed ID: 9309147
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956.
    Nagasu T, Yoshimatsu K, Rowell C, Lewis MD, Garcia AM.
    Cancer Res; 1995 Nov 15; 55(22):5310-4. PubMed ID: 7585593
    [Abstract] [Full Text] [Related]

  • 4. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
    Sun J, Qian Y, Hamilton AD, Sebti SM.
    Oncogene; 1998 Mar 15; 16(11):1467-73. PubMed ID: 9525745
    [Abstract] [Full Text] [Related]

  • 5. Development of highly potent inhibitors of Ras farnesyltransferase possessing cellular and in vivo activity.
    Leftheris K, Kline T, Vite GD, Cho YH, Bhide RS, Patel DV, Patel MM, Schmidt RJ, Weller HN, Andahazy ML, Carboni JM, Gullo-Brown JL, Lee FY, Ricca C, Rose WC, Yan N, Barbacid M, Hunt JT, Meyers CA, Seizinger BR, Zahler R, Manne V.
    J Med Chem; 1996 Jan 05; 39(1):224-36. PubMed ID: 8568812
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB, Omer CA, Abrams MT, Bhimnathwala HG, Brucker MJ, Buser CA, Davide JP, deSolms SJ, Dinsmore CJ, Ellis-Hutchings MS, Kral AM, Liu D, Lumma WC, Machotka SV, Rands E, Williams TM, Graham SL, Hartman GD, Oliff AI, Heimbrook DC, Kohl NE.
    Cancer Res; 2001 Dec 15; 61(24):8758-68. PubMed ID: 11751396
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
    Lerner EC, Zhang TT, Knowles DB, Qian Y, Hamilton AD, Sebti SM.
    Oncogene; 1997 Sep 15; 15(11):1283-8. PubMed ID: 9315095
    [Abstract] [Full Text] [Related]

  • 8. Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells.
    Manne V, Yan N, Carboni JM, Tuomari AV, Ricca CS, Brown JG, Andahazy ML, Schmidt RJ, Patel D, Zahler R.
    Oncogene; 1995 May 04; 10(9):1763-79. PubMed ID: 7753553
    [Abstract] [Full Text] [Related]

  • 9. Farnesyl protein transferase inhibitors as potential cancer chemopreventives.
    Kelloff GJ, Lubet RA, Fay JR, Steele VE, Boone CW, Crowell JA, Sigman CC.
    Cancer Epidemiol Biomarkers Prev; 1997 Apr 04; 6(4):267-82. PubMed ID: 9107432
    [Abstract] [Full Text] [Related]

  • 10. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
    Sebti SM, Hamilton AD.
    Oncogene; 2000 Dec 27; 19(56):6584-93. PubMed ID: 11426643
    [Abstract] [Full Text] [Related]

  • 11. Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion.
    Sun J, Qian Y, Hamilton AD, Sebti SM.
    Cancer Res; 1995 Oct 01; 55(19):4243-7. PubMed ID: 7671229
    [Abstract] [Full Text] [Related]

  • 12. Design and in vivo analysis of potent non-thiol inhibitors of farnesyl protein transferase.
    Anthony NJ, Gomez RP, Schaber MD, Mosser SD, Hamilton KA, O'Neil TJ, Koblan KS, Graham SL, Hartman GD, Shah D, Rands E, Kohl NE, Gibbs JB, Oliff AI.
    J Med Chem; 1999 Aug 26; 42(17):3356-68. PubMed ID: 10464022
    [Abstract] [Full Text] [Related]

  • 13. [Inhibitors of Ras farnesylation: tomorrow's anticancer agents?].
    Perrin D, Halazy S, Hill B.
    Bull Cancer; 1997 Jun 26; 84(6):635-42. PubMed ID: 9295868
    [Abstract] [Full Text] [Related]

  • 14. Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor.
    Omer CA, Chen Z, Diehl RE, Conner MW, Chen HY, Trumbauer ME, Gopal-Truter S, Seeburger G, Bhimnathwala H, Abrams MT, Davide JP, Ellis MS, Gibbs JB, Greenberg I, Koblan KS, Kral AM, Liu D, Lobell RB, Miller PJ, Mosser SD, O'Neill TJ, Rands E, Schaber MD, Senderak ET, Oliff A, Kohl NE.
    Cancer Res; 2000 May 15; 60(10):2680-8. PubMed ID: 10825141
    [Abstract] [Full Text] [Related]

  • 15. Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice.
    Mangues R, Corral T, Kohl NE, Symmans WF, Lu S, Malumbres M, Gibbs JB, Oliff A, Pellicer A.
    Cancer Res; 1998 Mar 15; 58(6):1253-9. PubMed ID: 9515813
    [Abstract] [Full Text] [Related]

  • 16. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects.
    Feldkamp MM, Lau N, Guha A.
    Oncogene; 1999 Dec 09; 18(52):7514-26. PubMed ID: 10602510
    [Abstract] [Full Text] [Related]

  • 17. Farnesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant phenotype.
    Yan N, Ricca C, Fletcher J, Glover T, Seizinger BR, Manne V.
    Cancer Res; 1995 Aug 15; 55(16):3569-75. PubMed ID: 7627966
    [Abstract] [Full Text] [Related]

  • 18. Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice.
    Liu M, Bryant MS, Chen J, Lee S, Yaremko B, Li Z, Dell J, Lipari P, Malkowski M, Prioli N, Rossman RR, Korfmacher WA, Nomeir AA, Lin CC, Mallams AK, Doll RJ, Catino JJ, Girijavallabhan VM, Kirschmeier P, Bishop WR.
    Cancer Chemother Pharmacol; 1999 Aug 15; 43(1):50-8. PubMed ID: 9923541
    [Abstract] [Full Text] [Related]

  • 19. Resistance of a variant ras-transformed cell line to phenotypic reversion by farnesyl transferase inhibitors.
    Prendergast GC, Davide JP, Lebowitz PF, Wechsler-Reya R, Kohl NE.
    Cancer Res; 1996 Jun 01; 56(11):2626-32. PubMed ID: 8653708
    [Abstract] [Full Text] [Related]

  • 20. Farnesyltransferase as a target for anticancer drug design.
    Qian Y, Sebti SM, Hamilton AD.
    Biopolymers; 1997 Jun 01; 43(1):25-41. PubMed ID: 9174410
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.